Cucurbitacin B inhibits growth and induces apoptosis through the JAK2/STAT3 and MAPK pathways in SH-SY5Y human neuroblastoma cells

Molecular Medicine Reports

Volumn 10, Issue 1, 2014, Pages 89-94

  Zheng, Qian ^a   Liu, Yunyi ^a   Liu, Weiwei ^a   Ma, Fengyun ^a   Zhou, Y I ^a   Chen, Mingjie ^a   Chang, Junli ^a   Wang, Yuesheng ^a   Yang, Guangxiao ^a   He, Guangyuan ^a  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

Apoptosis; Cell cycle arrest; Cucurbitacin B; SH SY5Y cells

Indexed keywords

BCL2 ASSOCIATED X PROTEIN; CUCURBITACIN; CUCURBITACIN B; CYCLIN B1; CYCLIN DEPENDENT KINASE 1; JANUS KINASE 2; LIPOCORTIN 5; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE P38; STAT3 PROTEIN; STRESS ACTIVATED PROTEIN KINASE; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; JAK2 PROTEIN, HUMAN; PROTEIN BAX; PROTEIN BCL 2; TRITERPENE;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CELL CYCLE ARREST; CELL CYCLE M PHASE; CELL PROLIFERATION; CELL SURVIVAL; CONTROLLED STUDY; DRUG MECHANISM; GENE EXPRESSION; GENE PRODUCT; GROWTH INHIBITION; HUMAN; HUMAN CELL; NEUROBLASTOMA CELL; STAINING; DRUG EFFECTS; G2 PHASE CELL CYCLE CHECKPOINT; M PHASE CELL CYCLE CHECKPOINT; METABOLISM; NEUROBLASTOMA; PATHOLOGY; PHOSPHORYLATION; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; APOPTOSIS; BCL-2-ASSOCIATED X PROTEIN; CELL LINE, TUMOR; CELL PROLIFERATION; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; G2 PHASE CELL CYCLE CHECKPOINTS; HUMANS; JANUS KINASE 2; M PHASE CELL CYCLE CHECKPOINTS; NEUROBLASTOMA; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-BCL-2; SIGNAL TRANSDUCTION; STAT3 TRANSCRIPTION FACTOR; TRITERPENES;

EID: 84901433492     PISSN: 17912997     EISSN: 17913004     Source Type: Journal    
DOI: 10.3892/mmr.2014.2175     Document Type: Article

References (35)

1. Brodeur GM. Neuroblastoma: Biological insights into a clinical enigma. Nat Rev Cancer 3: 203-216, 2003. (Pubitemid 37328872)
2. Fisher JP and Tweddle DA. Neonatal neuroblastoma. Semin Fetal Neonatal Med 17: 207-215, 2012.
3. Zhang Y, Ouyang D, Xu L, Ji Y, Zha Q, Cai J and He X. Cucurbitacin B induces rapid depletion of the G-actin pool through reactive oxygen species-dependent actin aggregation in melanoma cells. Acta Biochim Biophys Sin (Shanghai) 43: 556-567, 2011.
4. Jayaprakasam B, Seeram NP and Nair MG. Anticancer and antiinflammatory activities of cucurbitacins from Cucurbita andreana. Cancer Lett 189: 11-16, 2003. (Pubitemid 35351514)
5. Chen JC, Chiu MH, Nie RL, Cordell GA and Qiu SX. Cucurbitacins and cucurbitane glycosides: structures and biological activities. Nat Prod Rep 22: 386-399, 2005.
6. Dzubak P, Hajduch M, Vydra D, et al. Pharmacological activities of natural triterpenoids and their therapeutic implications. Nat Prod Rep 23: 394-411, 2006. (Pubitemid 43847140)
7. Takasaki M, Konoshima T, Murata Y, et al. Anticarcinogenic activity of natural sweeteners, cucurbitane glycosides, from Momordica grosvenori. Cancer Lett 198: 37-42, 2003. (Pubitemid 37289101)
8. Liu T, Peng H, Zhang M, Deng Y and Wu Z. Cucurbitacin B, a small molecule inhibitor of the Stat3 signaling pathway, enhances the chemosensitivity of laryngeal squamous cell carcinoma cells to cisplatin. Eur J Pharmacol 641: 15-22, 2010.
9. Promkan M, Dakeng S, Chakrabarty S, Bögler O and Patmasiriwat P. The effectiveness of cucurbitacin B in BRCA1 defective breast cancer cells. PLoS One 8: e55732, 2013.
10. Haritunians T, Gueller S, Zhang L, et al. Cucurbitacin B induces differentiation, cell cycle arrest, and actin cytoskeletal alterations in myeloid leukemia cells. Leuk Res 32: 1366-1373, 2008.
11. Dakeng S, Duangmano S, Jiratchariyakul W, U-Pratya Y, Bögler O and Patmasiriwat P. Inhibition of Wnt signaling by cucurbitacin B in breast cancer cells: reduction of Wnt-associated proteins and reduced translocation of galectin-3-mediated β-catenin to the nucleus. J Cell Biochem 113: 49-60, 2012.
12. Yin D, Wakimoto N, Xing H, et al. Cucurbitacin B markedly inhibits growth and rapidly affects the cytoskeleton in glioblastoma multiforme. Int J Cancer 123: 1364-1375, 2008.
13. Thoennissen NH, Iwanski GB, Doan NB, et al. Cucurbitacin B induces apoptosis by inhibition of the JAK/STAT pathway and potentiates antiproliferative effects of gemcitabine on pancreatic cancer cells. Cancer Res 69: 5876-5884, 2009.
14. Liu T, Zhang M, Zhang H, Sun C and Deng Y. Inhibitory effects of cucurbitacin B on laryngeal squamous cell carcinoma. Eur Arch Otorhinolaryngol 265: 1225-1232, 2008.
15. Oh H, Mun YJ, Im SJ, Lee SY, Song HJ, Lee HS and Woo WH. Cucurbitacins from Trichosanthes kirilowii as the inhibitory components on tyrosinase activity and melanin synthesis of B16/F10 melanoma cells. Planta Med 68: 832-833, 2002. (Pubitemid 35177631)
16. Lee DH, Thoennissen NH, Goff C, et al. Synergistic effect of low-dose cucurbitacin B and low-dose methotrexate for treatment of human osteosarcoma. Cancer Lett 306: 161-170, 2011.
17. Jin HR, Jin X, Dat NT and Lee JJ. Cucurbitacin B suppresses the transactivation activity of RelA/p65. J Cell Biochem 112: 1643-1650, 2011.
18. Gheeya JS, Chen QR, Benjamin CD, et al. Screening a panel of drugs with diverse mechanisms of action yields potential therapeutic agents against neuroblastoma. Cancer Biol Ther 8: 2386-2395, 2009.
19. Zhang M, Zhang H, Sun C, Shan X, Yang X, Li-Ling J and Deng YH. Targeted constitutive activation of signal transducer and activator of transcription 3 in human hepatocellular carcinoma cells by cucurbitacin B. Cancer Chemother Pharmacol 63: 635-642, 2009.
20. Mirzayans R, Andrais B, Scott A and Murray D. New insights into p53 signaling and cancer cell response to DNA damage: implications for cancer therapy. J Biomed Biotechnol 2012: 170325, 2012.
21. Kiu H and Nicholson SE. Biology and significance of the JAK/STAT signalling pathways. Growth Factors 30: 88-106, 2012.
22. O'Shea JJ, Gadina M and Schreiber RD. Cytokine signaling in 2002: new surprises in the Jak/Stat pathway. Cell 109 (Suppl): S121-S131, 2002. (Pubitemid 34457857)
23. Yu H and Jove R. The STATs of cancer - new molecular targets come of age. Nat Rev Cancer 4: 97-105, 2004. (Pubitemid 38198738)
24. Yu H, Pardoll D and Jove R. STATs in cancer inflammation and immunity: a leading role for STAT3. Nat Rev Cancer 9: 798-809, 2009.
25. Liu YY, Zheng Q, Fang B, et al. Germacrone induces apoptosis in human hepatoma HepG2 cells through inhibition of the JAK2/STAT3 signalling pathway. J Huazhong Univ Sci Technolog Med Sci 33: 339-345, 2013.
26. Epling-Burnette PK, Liu JH, Catlett-Falcone R, et al. Inhibition of STAT3 signaling leads to apoptosis of leukemic large granular lymphocytes and decreased Mcl-1 expression. J Clin Invest 107: 351-362, 2001.
27. Nam S, Xie J, Perkins A, et al. Novel synthetic derivatives of the natural product berbamine inhibit Jak2/Stat3 signaling and induce apoptosis of human melanoma cells. Mol Oncol 6: 484-493, 2012.
28. Bill MA, Nicholas C, Mace TA, et al. Structurally modified curcumin analogs inhibit STAT3 phosphorylation and promote apoptosis of human renal cell carcinoma and melanoma cell lines. PLoS One 7: e40724, 2012.
29. Um HJ, Min KJ, Kim DE and Kwon TK. Withaferin A inhibits JAK/STAT3 signaling and induces apoptosis of human renal carcinoma Caki cells. Biochem Biophys Res Commun 427: 24-29, 2012.
30. Park KR, Nam D, Yun HM, et al. β-Caryophyllene oxide inhibits growth and induces apoptosis through the suppression of PI3K/AKT/mTOR/S6K1 pathways and ROS-mediated MAPKs activation. Cancer Lett 312: 178-188, 2011.
31. Scuteri A, Galimberti A, Maggioni D, et al. Role of MAPKs in platinum-induced neuronal apoptosis. Neurotoxicology 30: 312-319, 2009.
32. Boutros T, Chevet E and Metrakos P. Mitogen-activated protein (MAP) kinase/MAP kinase phosphatase regulation: roles in cell growth, death, and cancer. Pharmacol Rev 60: 261-310, 2008.
33. Ishdorj G, Johnston JB and Gibson SB. Cucurbitacin-I (JSI-124) activates the JNK/c-Jun signaling pathway independent of apoptosis and cell cycle arrest in B leukemic cells. BMC Cancer 11: 268, 2011.
34. Cory S and Adams JM: The Bcl2 family: regulators of the cellular life-or-death switch. Nat Rev Cancer 2: 647-656, 2002. (Pubitemid 37328916)
35. Fuster JJ, Sanz-González SM, Moll UM and Andrés V: Classic and novel roles of p53: prospects for anticancer therapy. Trends Mol Med 13: 192-199, 2007. (Pubitemid 46687126)